Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
IVERIC bio, Inc. - Common Stock
(NQ:
ISEE
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 10, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about IVERIC bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Iveric Bio Shares Shoot Higher Following Positive Top-line Data From Late-Stage Geographic Atrophy Study
↗
September 06, 2022
Iveric Bio (NASDAQ: ISEE) announced positive topline results from the second Phase 3 clinical trial of Zimura (avacincaptad pegol) for the treatment of geographic atrophy (GA).
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
September 06, 2022
Via
Benzinga
IVERIC bio Stock Soars After Encouraging Geographic Atrophy Trial Data
↗
September 06, 2022
IVERIC bio Inc (NASDAQ: ISEE) announced positive data from the second Phase 3 trial of Zimura (avacincaptad pegol) for geographic atrophy (GA).
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
September 06, 2022
Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!
Via
InvestorPlace
What 5 Analyst Ratings Have To Say About IVERIC bio
↗
August 02, 2022
Within the last quarter, IVERIC bio (NASDAQ:ISEE) has observed the following analyst ratings:
Via
Benzinga
IVERIC bio Shares Jump On Debt Financing To Fund Zimura Launch
↗
July 26, 2022
Via
Benzinga
Recap: IVERIC bio Q2 Earnings
↗
July 26, 2022
IVERIC bio (NASDAQ:ISEE) reported its Q2 earnings results on Tuesday, July 26, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy
September 06, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2022
From
IVERIC bio, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
August 25, 2022
Via
Benzinga
Earnings Scheduled For July 26, 2022
↗
July 26, 2022
Companies Reporting Before The Bell • General Motors (NYSE:GM) is likely to report quarterly earnings at $1.30 per share on revenue of $34.59 billion.
Via
Benzinga
Short Volatility Alert: IVERIC bio, Inc.
↗
July 21, 2022
On Wednesday, shares of IVERIC bio, Inc. (NASDAQ: ISEE) experienced volatile short activity. After the activity, the stock price went up +1.70% to $11.95. The overall sentiment for ISEE has been...
Via
Benzinga
Expert Ratings for IVERIC bio
↗
July 07, 2022
IVERIC bio (NASDAQ:ISEE) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Why Several Chinese Stocks Traded Higher; Here Are 58 Biggest Movers From Yesterday
↗
August 26, 2022
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) surged 95.3% to close at $0.2580 on Thursday after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and announced a price target...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
August 17, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 10, 2022
From
IVERIC bio, Inc.
Via
Business Wire
7 Cheap Biotech Stocks to Buy Now
↗
August 03, 2022
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector.
Via
InvestorPlace
Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022
August 03, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022
↗
August 02, 2022
Upgrades
Via
Benzinga
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2022
From
IVERIC bio, Inc.
Via
Business Wire
3 Biotech Stock Picks From This Wedbush Analyst
↗
July 27, 2022
While the S&P 500 index peaked in January and has had a rough year, the biotech sector peaked last August. For the time being, both have found a short-term and possible long-term bottom in June.
Via
Benzinga
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
↗
July 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Alibaba, General Electric And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
↗
July 26, 2022
Redbox Entertainment Inc. (NASDAQ: RDBX) rose 11.5% to $6.19 in pre-market trading after jumping 82% on Monday.
Via
Benzinga
Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results
July 26, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank
July 26, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Earnings Preview: IVERIC bio
↗
July 25, 2022
IVERIC bio (NASDAQ:ISEE) is set to give its latest quarterly earnings report on Tuesday, 2022-07-26. Here's what investors need to know before the announcement. Analysts estimate that IVERIC bio will...
Via
Benzinga
Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022
July 21, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® at American Society of Retina Specialists Meeting
July 16, 2022
From
IVERIC bio, Inc.
Via
Business Wire
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
↗
July 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®
July 05, 2022
From
IVERIC bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.